A new study in Lancet Digital Health identifies early warning symptoms like chest pain and dyspnea that are moderately associated with imminent sudden cardiac arrest. The research suggests that future digital technologies could combine these symptoms with biometric data to more precisely predict and potentially prevent these life-threatening events.
Biogen’s $7.3B M&A deal, layoffs; R&D shakeup at Pfizer, AstraZeneca; Scaling rare disease meds; Q2 earnings; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit
July 30, 2023